210 related articles for article (PubMed ID: 36109084)
1. Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model.
Kang J; Lee HJ; Lee J; Hong J; Hong Kim Y; Disis ML; Gim JA; Park KH
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36109084
[TBL] [Abstract][Full Text] [Related]
2. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
[TBL] [Abstract][Full Text] [Related]
3. An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice.
Bounds CE; Terry FE; Moise L; Hannaman D; Martin WD; De Groot AS; Suschak JJ; Dupuy LC; Schmaljohn CS
Hum Vaccin Immunother; 2017 Dec; 13(12):2824-2836. PubMed ID: 28575582
[TBL] [Abstract][Full Text] [Related]
4. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity.
Shah S; Cook KW; Symonds P; Weißer J; Skinner A; Al Omari A; Paston SJ; Pike I; Durrant LG; Brentville VA
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857526
[TBL] [Abstract][Full Text] [Related]
6. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.
Hamrouni S; Bras-Gonçalves R; Kidar A; Aoun K; Chamakh-Ayari R; Petitdidier E; Messaoudi Y; Pagniez J; Lemesre JL; Meddeb-Garnaoui A
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008093. PubMed ID: 32176691
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
[TBL] [Abstract][Full Text] [Related]
8. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
9. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.
Rojas JM; Rodríguez-Calvo T; Peña L; Sevilla N
Vaccine; 2011 Sep; 29(40):6848-57. PubMed ID: 21807057
[TBL] [Abstract][Full Text] [Related]
10. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
11. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors.
Suginobe N; Nakamura M; Takanashi Y; Ban H; Gotoh M
Clin Transl Oncol; 2023 Feb; 25(2):396-407. PubMed ID: 36138335
[TBL] [Abstract][Full Text] [Related]
13. MMP-7 derived peptides with MHC class-I binding motifs from canine mammary tumor tissue elicit strong antigen-specific T-cell responses in BALB/c mice.
Yadav PK; Gupta SK; Kumar S; Ghosh M; Yadav BS; Kumar D; Kumar A; Saini M; Kataria M
Mol Cell Biochem; 2021 Jan; 476(1):311-320. PubMed ID: 32970284
[TBL] [Abstract][Full Text] [Related]
14. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Promiscuous Epitope Peptide Derived From HSP70.
Matsui H; Hazama S; Tamada K; Udaka K; Irie A; Nishimura Y; Miyakawa T; Doi S; Nakajima M; Kanekiyo S; Tokumitsu Y; Shindo Y; Tomochika S; Yoshida S; Iida M; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Ueno T; Nagano H
J Immunother; 2019 Sep; 42(7):244-250. PubMed ID: 31398179
[TBL] [Abstract][Full Text] [Related]
16. Hsp90-peptide complexes stimulate antigen presentation through the class II pathway after binding scavenger receptor SREC-I.
Murshid A; Gong J; Calderwood SK
Immunobiology; 2014 Dec; 219(12):924-31. PubMed ID: 25155057
[TBL] [Abstract][Full Text] [Related]
17. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
[TBL] [Abstract][Full Text] [Related]
18. Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.
Bekri S; Rodney-Sandy R; Gruenstein D; Mei A; Bogen B; Castle J; Levey D; Cho HJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190376
[TBL] [Abstract][Full Text] [Related]
19. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease.
Kallinteris NL; Powell D; Blackwell CE; Kim M; Lu X; Wu S; Humphreys RE; Xu M; von Hofe E
Front Biosci; 2006 Jan; 11():46-58. PubMed ID: 16146713
[TBL] [Abstract][Full Text] [Related]
20. MHC-class-I expression in human breast cancer correlates with nuclear localization of the 90 kDa heat-shock-protein.
Gebhard B; Schütz G; Ecker RC; Steiner GE; Rudas M; Gnant M; Oehler R
Anticancer Res; 1999; 19(6B):5293-7. PubMed ID: 10697551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
